PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

NCT06274047 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Androgen Axis Suppression
Prostatectomy
Prostate Cancer

Interventions

DRUG: Apalutamide
DRUG: Androgen Deprivation Therapy

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]